Evotec, Vifor JV To Fight Kidney Disease
Duo’s Discovery Plan To Use Patient-Driven Data
Evotec’s CSO says its new joint venture with Vifor will use patient-driven data to identify and develop targeted therapies to treat kidney disease with.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.